GMP-Ready Transfection Solution for AAV and LV Viral Vector Manufacturing
1012 vg/mL Titers | 5-10× Yield Boost| 50% Cost Savings
Hieff Trans™ UltraAAV Transfection Reagent is a next-generation solution powered by AI-designed PEI engineering and targeted screening, specifically optimized for high-yield AAV and lentiviral (LV) manufacturing. Ideal for HEK293 suspension systems, this innovative reagent delivers superior transfection efficiency and ensures consistent, reliable quality across both Research Use Only (RUO) and GMP grades. By supporting seamless scaling from early-stage research to commercial production, it provides a robust and dependable platform for modern viral vector workflows.
Through advanced technological innovation, UltraAAV achieves dual advantages of exceptional performance and significant cost savings. Compared to standard PEI or liposome alternatives, it boosts the AAV full-capsid ratio by 200% and yields high titers up to 10¹² vg/mL, all while reducing reagent consumption by 50%. This unprecedented efficiency makes it a highly cost-effective powerhouse for scaling up viral production without compromising quality.
Key Highlights
Performance Data
Multi-Project Validation
1) AAV9 Project Validation
Figure. Comparison of AAV9 packaging efficiency.
UltraAAV showed higher AAV9 packaging efficiency and genome titers than supplier P at both 1:0.5 and 1:1 ratios, with optimal yield at 1:0.5.
2) AAV5 Project Validation
Figure. Comparison of AAV5 packaging efficiency.
UltraAAV exhibited superior packaging efficiency at 1:0.5 and 1:0.75 DNA-to-reagent ratios compared to Supplier P, which was tested at 1:0.5 and 1:1 ratios.
Enhanced Lentiviral (LV) Titer
Figure. Comparison of LV packaging titers.
Three-plasmid packaging using YS-UltraAAV resulted in viral yields comparable to other leading PEI reagents.
Higher viral titers across multiple AAV serotypes
Figure. AAV multi-project validation.
Hieff Trans™ UltraAAV yielded superior titers across AAV2, AAV5, AAV8, and AAV9 compared to leading PEIs. AAVs were produced in suspension 293F cells (1 µg DNA/10⁶ cells) and harvested at 72 h.
Half the Reagent, Same Viral Titer
Achieve comparable viral output with 50% less reagent compared to leading alternatives.
Figure. Equivalent or superior yields and capsid integrity are achieved using only half the reagent amount,
substantially lowering production costs and improving cell viability.
Consistent Transfection Efficiency During Scale-up Workflows
Flexibility for Large-Scale Production
The transfection complex volume can be reduced to 1%, and it has a stability of up to 6 hours. These characteristics together provide great convenience and cost-effectiveness for the large-scale preparation of AAV viral vectors.
Figure Transfection complex volume and stability
Strong Stability
(A). Three-batch consistency(AAV9 -VG)
(B). Three-batch consistency(AAV9 Capsid Integrity)
Figure Stability evaluation in the AAV9 project.
Hieff TransTM demonstrated consistent performance across three GMP-grade batches and passed both accelerated and transport stability testing, ensuring reliable and stable supply.
Unlock Creativity with Superior Delivery Performance
AI-powered Novel Transfection Reagent Development Platform
Leveraging an AI-powered and high-throughput screening platform for transfection reagent development, Yeasen Biotechnology has successfully launched a series of transfection reagents covering three major fields: basic scientific research, recombinant protein/antibody production, and viral vector manufacturing.
This platform provides researchers with high-quality foundational transfection reagents. It's high-performance products support large-scale antibody and protein production; and it also offers GMP-grade transfection reagents for viral packaging, meeting the demands of large-scale AAV and lentiviral (LV) vector production, thereby robustly supporting drug development and manufacturing applications.
FAQs
Product Details
